Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Myriad Genetics (MYGN) Total Debt (2016 - 2025)

Historic Total Debt for Myriad Genetics (MYGN) over the last 9 years, with Q3 2025 value amounting to $119.5 million.

  • Myriad Genetics' Total Debt rose 20641.03% to $119.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $119.5 million, marking a year-over-year increase of 20641.03%. This contributed to the annual value of $39.6 million for FY2024, which is 285.71% up from last year.
  • Latest data reveals that Myriad Genetics reported Total Debt of $119.5 million as of Q3 2025, which was up 20641.03% from $59.4 million recorded in Q2 2025.
  • Myriad Genetics' 5-year Total Debt high stood at $119.5 million for Q3 2025, and its period low was $38.4 million during Q2 2023.
  • Over the past 4 years, Myriad Genetics' median Total Debt value was $39.0 million (recorded in 2024), while the average stood at $55.8 million.
  • Its Total Debt has fluctuated over the past 5 years, first surged by 325806.45% in 2021, then surged by 104.17% in 2024.
  • Over the past 4 years, Myriad Genetics' Total Debt (Quarter) stood at $104.1 million in 2021, then tumbled by 63.02% to $38.5 million in 2023, then rose by 2.86% to $39.6 million in 2024, then skyrocketed by 201.77% to $119.5 million in 2025.
  • Its Total Debt stands at $119.5 million for Q3 2025, versus $59.4 million for Q2 2025 and $59.3 million for Q1 2025.